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Polymer Everolimus-Eluting Stent Relative
to Contemporary Drug-Eluting Stents With
Biodegradable Polymer Coatings Assessed
Ex Vivo in a Swine Shunt Model
Fumiyuki Otsuka, MD, PHD,* Qi Cheng, MD,* Kazuyuki Yahagi, MD,* Eduardo Acampado, DVM,*
Alexander Sheehy, MS,y Saami K. Yazdani, PHD,* Kenichi Sakakura, MD,* Kristina Euller,*
Laura E.L. Perkins, DVM, PHD,y Frank D. Kolodgie, PHD,* Renu Virmani, MD,* Michael Joner, MD*ABSTRACTOBJECTIVES This study sought to evaluate whether the permanent ﬂuoropolymer-coated Xience Xpedition
everolimus-eluting stent (Xience-EES) exhibits lower acute thrombogenicity compared with contemporary drug-eluting
stents (DES) with biodegradable polymer coatings in an acute swine shunt model.
BACKGROUND Previous pre-clinical and clinical experience suggests that several factors may inﬂuence the predis-
position for acute thrombus formation of polymer-coated DES, including stent design and the polymer coating
technology. It remains unclear whether relevant differences exist with respect to acute thrombogenicity, particularly
between current commercial stent designs using permanent polymers and those using biodegradable polymers.
METHODS An ex vivo carotid to jugular arteriovenous porcine shunt model involving a test circuit of 3 in-line
stents, was used to test acute thrombogenicity, where Xience-EES (n ¼ 24) was compared with 4 CE-marked DES
with biodegradable polymer coatings (BioMatrix Flex, Synergy, Nobori, and Orsiro [n ¼ 6 each]). After 1 h of circulation,
platelet aggregation in whole mount stents was evaluated by confocal microscopy with immunoﬂuorescent staining
against dual platelet markers (CD61/CD42b) along with scanning electron microscopy.
RESULTS Xience-EES showed the least percentage of thrombus-occupied area as compared with the biodegradable
polymer-coated DES, with a signiﬁcant difference compared with BioMatrix Flex and Synergy (mean differences:
[BioMatrix Flex: 15.54, 95% conﬁdence interval [CI]: 11.34 to 19.75, p < 0.001; Synergy: 8.64, 95% CI: 4.43 to 12.84,
p < 0.001; Nobori: 4.22, 95% CI: -0.06 to 8.49, p ¼ 0.055; Orsiro: 2.95, 95% CI: -1.26 to 7.15, p ¼ 0.286). The
number of cell nuclei on strut surfaces was also the least in Xience-EES, with a signiﬁcant difference relative to
BioMatrix Flex, Nobori, and Orsiro (mean ratios: BioMatrix Flex: 4.73, 95% CI: 2.46 to 9.08, p < 0.001; Synergy: 1.44,
95% CI: 0.75 to 2.76, p ¼ 0.51; Nobori: 5.97, 95% CI: 3.11 to 11.44, p < 0.001; Orsiro: 5.16, 95% CI: 2.69 to 9.91,
p < 0.001).
CONCLUSIONS Xience-EES’s overall design confers acute thromboresistance relative to contemporary DES with
biodegradable coatings, with less platelet aggregation versus BioMatrix Flex and Synergy, and less inﬂammatory cell
attachment versus BioMatrix Flex, Nobori, and Orsiro, in an ex vivo swine shunt model, which lends support to reported
clinical ﬁndings of lower early stent thrombosis. (J Am Coll Cardiol Intv 2015;8:1248–60) © 2015 by the American
College of Cardiology Foundation.
AB BR E V I A T I O N S
AND ACRONYM S
BES = biolimus-eluting stent(s)
BMS = bare-metal stent(s)
CI = conﬁdence interval
DAPI = 40 ,6-diamindino-2-
phenylindole
DES = drug-eluting stent(s)
EES = everolimus-eluting
stent(s)
SEM = scanning electron
microscopy
SES = sirolimus-eluting
stent(s)
ST = stent thrombosis
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1249E arly stent thrombosis (ST) remains a criticalissue even with the use of contemporarydrug-eluting stents (DES), where the indica-
tions for percutaneous coronary intervention have
been expanded to include more complex lesions
(1,2). Histomorphologic assessment of stents at au-
topsy from patients presenting with acute coronary
syndrome from our laboratory has demonstrated an
association of early ST with necrotic core prolapse,
medial tear, and incomplete stent apposition (3).
In addition to morphologic criteria of the underlying
plaque, stent design, choice of polymer coating, its
application (e.g., use of primer, coating integrity),
and drugs may also inﬂuence acute thrombogenicity
as experimental studies in modiﬁed Chandler loops
have shown that durable polymer-coated stents with
thin struts exhibit less acute thrombogenicity with
respect to platelet aggregation as compared to un-
coated or stents with thicker struts (4). Clinical studies
have also demonstrated a lower prevalence of early
ST in durable polymer-coated DES as compared with
bare-metal stents (BMS), where the cobalt-chromium
everolimus-eluting stents (EES) exhibit the least
prevalence of early ST relative to BMS and the other
durable polymer-coated DES (5–7). Considerable
attention has been tied to the impact of polymer coat-
ings on acute thrombogenicity and whether durable
polymers exert differential effects in this regard
compared with more recently introduced biodegrad-
able stent coatings. In the absence of randomized clin-
ical trials focused on acute thrombogenicity among
comparable state-of-the-art DES, dedicated pre-
clinical studies speciﬁcally designed to address the
impact of stents with divergent conﬁguration of indi-
vidual components on acute thrombogenicity remain
an important measure to reveal differential pro-
coagulatory device effects.
Therefore, the current study was designed
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in Xience Xpedition EES (Xience-EES) (Abbott
Vascular, Santa Clara, California) with dura-
ble polymer coating technology with 4 CE-
marked DES with biodegradable polymer
coatings in an ex vivo porcine arteriovenous
shunt model.METHODS
EXPERIMENTAL SET-UP AND TEST GROUPS.
A porcine ex vivo arteriovenous shunt model
was established to study the extent of
platelet adherence, thrombus formation, and
acute inﬂammation in Xience-EES (n ¼ 24)
compared with 4 contemporary DES with biodegrad-
able coatings: 1) BioMatrix Flex biolimus-eluting
stent (BES) (Biosensors, Newport Beach, California)
(n ¼ 6); 2) Nobori-BES (Terumo, Tokyo, Japan) (n ¼ 6);
3) Synergy-EES (Boston Scientiﬁc, Natick, Massachu-
setts) (n ¼ 6); and 4) Orsiro sirolimus-eluting stent
(SES) (Biotronik AG, Bülach, Switzerland) (n ¼ 6)
(Figure 1, Online Figure 1).
Each shunt model had 3 stents and each animal had
2 shunt experiments. However, there was 1 animal
that achieved only the ﬁrst shunt experiment because
of deterioration of general condition during the sec-
ond shunt experiment. Therefore, 1 additional shunt
experiment was performed in another animal. Thus,
a total of 48 stents were deployed in 16 shunts from
9 swine for the assessment of acute thrombogenicity.
PORCINE ARTERIOVENOUS SHUNT MODEL. Three con-
secutive DES were deployed at nominal pressure
in Sylgard (Dow Corning, Midland, Michigan) mock
vascular phantoms (8). The Sylgard conduits (inner
diameter: 2.70 mm  11 cm length) were fabricated
using 316L stainless steel tubing and commercial
elastomer kit (Sylgard-184, Dow Corning). Beforelar, Santa Clara, California. This study was sponsored
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FIGURE 1 Acute Swine Shunt Model and Gross Photos of Mount Stents
(A) A porcine ex vivo carotid to jugular arteriovenous (AV) shunt model involving a test circuit of 3 in-line stents within a silastic tube was used to test thrombogenicity
with 1 h of circulating blood. (B) Schematic illustration of the acute shunt model. (C) Gross photos of 3 in-line stents within a silastic tube. (D) The stents were bisected
longitudinally; one-half for immunoﬂuorescent staining against dual platelet markers (CD61/CD42b) with confocal microscopic (CM) assessment and the other for
scanning electron microscopy (SEM), to identify the extent of platelet adherence in whole mount stents.
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1250deploying stents, the tubing was mounted in a ﬁxed
apparatus. The conduit was then ﬁlled with autolo-
gous serum and stents were expanded to a 3.0-mm
diameter at nominal pressure. The extent of platelet
aggregation to struts was studied after exposure to
circulating blood for 1 h through an established arte-
riovenous carotid to jugular shunt.
Target blood activated clotting times between 150 s
and 190 s were achieved with intravenous heparin
(100 IU/kg) dosing without antiplatelet agents such
as clopidogrel or aspirin as the current study was
speciﬁcally designed to examine inherent platelet-
mediated thrombus formation induced by contem-
porary DES of differential design. Two shunts werestudied in each animal where positioning of DES in
each tube was deﬁned to include either 2 ﬂanking
Xience-EES or biodegradable polymer DES, respec-
tively, separated by their respective counterparts
(Figure 1). Shunt positions were numerically noted as
proximal, mid, and distal relative to the arterial side.
Before establishing blood ﬂow through the circuit,
stents were primed with autologous platelet-poor
plasma. During experiments, stented tubing was
maintained in a 37C water bath and ﬂow rates
were monitored continuously using an ultrasonic
transducer (Transonic, Ithaca, New York). At the
conclusion of each run, stents were gravity perfused
with Ringer’s lactate, ﬁxed in 10% neutral buffered
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1251formalin, and bisected longitudinally. One-half of
each stent was immunostained using speciﬁc platelet
markers relevant for aggregation of thrombocytes
and examined en face by confocal microscopy,
whereas the other one-half was processed for scan-
ning electron microscopy (SEM).
ASSESSMENT OF PLATELET AGGREGATION. Confoca l
microscopy . Stent halves were incubated overnight
in 4C in an antibody cocktail directed against speciﬁc
platelet markers: CD61 as a marker of platelet aggre-
gation (Immunotech, IM0540, dilution 1:100, Beck-
man Coulter, Brea, California) and CD42b as a marker
of platelet adhesion (sc-7070, dilution 1:40, Santa
Cruz Biotechnology, Dallas, Texas) to capture both
originating and propagated platelet thrombus. Posi-
tive staining was visualized using a secondary anti-
body conjugated to an Alexa Fluor 488 ﬂuorophore
(Life Technologies, Carlsbad, California). After im-
munostaining, nuclei were counterstained with 40,6-
diamindino-2-phenylindole (DAPI) and stents were
mounted en face on glass slides and coverslipped in
aqueous mounting media. The entire stent surface
was scanned using pre-determined “ﬁxed” parame-
ters incorporating a tile feature with Z stack imaging
(LSM 700, Zen 2011 software, Zeiss, Oberkochen,
Germany). The positive area of platelet staining was
analyzed by proprietary software (Zen image analysis
tool) within deﬁned regions of interest, which were
maintained for all examined samples (40 mm2) and
reported as absolute positive area (mm2) of the device
and percentage of positive area, which was calculated
by dividing the absolute positive area by a pre-
deﬁned region of interest spanning the entire bisec-
ted segment of the stented artery. In addition, the
relative percentage of positive staining was also
calculated by dividing the absolute positive area by
total stent surface area measured by morphometry.
The total number of platelet aggregate clots >0.1 mm2
was also quantiﬁed from composite confocal and SEM
images of stent halves.
Scann ing electron microscopy . The remaining
stent halves were processed for SEM. Specimens were
dehydrated, critically point dried, and sputter-coated
with gold. Digital images were acquired using a
Hitachi SEM (model 3600N, Tokyo, Japan). Low
power (15 magniﬁcation) images of the entire
luminal surface were collected to assess the extent of
thrombus attached to the strut surfaces. Stitched
low power montage images of the entire luminal
surface were then assembled into a single image.
Higher power photographs of regions of interest were
also taken at incremental magniﬁcations of (50,
200, 600, and 2,000). The total number ofplatelet aggregate clots >0.1 mm2 were also quanti-
ﬁed from composite SEM images of stent halves.
QUANTIFICATION OF INFLAMMATORY CELLS.
DAPI-positive nuclei were counted in 3 representative
regions of maximal inﬂammatory cell adhesion
within the proximal, mid, and distal regions of
each stent. As both erythrocytes and thrombocytes
lack nuclei, adherent cells were considered to be of
leukocyte origin (i.e., inﬂammatory cells). The mean
number of inﬂammatory cells was derived and cell
numbers (density) were expressed as the mean total
nuclei per mm2.
BLOOD COAGULATION AND PLATELET FUNCTION.
Blood was serially drawn for coagulation and platelet
function proﬁles pre-shunt (baseline) and after each
experimental run to conﬁrm the absence of coagula-
tion and platelet function abnormalities. Indices of
coagulation, platelet number, and function included
platelet count, prothrombin time, partial thrombo-
plastin time, and light transmission aggregometry.
In addition, pig platelet factor 4 release was also
assessed in collected plasma using a commercial
ELISA kit (ab156530, Abcam, Cambridge, Massachu-
setts) (sensitivity ¼ 0.1 ng/ml) according to the
manufacturer’s instruction.
STATISTICAL ANALYSIS. Nested generalized linear
mixed models were used to investigate group differ-
ences in consideration of multiple measurements per
individual. Within these models, the experimental
factor variables animal, shunt number, and linear
position were considered as nested random effects.
The Akaike information criterion was evaluated for
the goodness of model ﬁt, and only number of cell
nuclei on stent surface was logarithmically trans-
formed before analysis. The analyses were performed
by R software (version 3.1.0, R Core Team, Vienna,
Austria) incorporating the multcomp R package (9).
The statistical tests were 2-tailed and a value of
p < 0.05 was considered to indicate statistical signif-
icance. Dunnett correction for many-to-1 comparisons
was used to implement adjustment of p values and
conﬁdence interval lengths for multiple testing (10).RESULTS
BLOOD COAGULATION AND PLATELET FUNCTION.
There was no evidence of blood coagulation and
platelet function abnormalities in any of the animals
studied, and plasma pig platelet factor 4 release was
below detection limit (Online Table 1). The mean
activated clotting time was between 86 to 106 s at
baseline, between 142 and 231 s during the ﬁrst
FIGURE 2 Representative CM Images of BioMatrix Flex-BES, Synergy-EES, Nobori-BES, Orsiro-SES, and Xience-EES With
Immunoﬂuorescent Staining Against Dual Platelet Markers (CD61/CD42b) in a Swine Shunt Model
Low- and high-power confocal microscopic (CM) images showing least thrombus-occupied area in Xience Xpedition (Xience-EES) as compared
with the other 4 CE-marked biodegradable polymer-coated drug-eluting stents. Note stent struts of Xience-EES are barely identiﬁed.
BES ¼ biolimus-eluting stent(s); SES ¼ sirolimus-eluting stent(s).
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1252shunt, and between 118 and 253 s during the second
shunt (Online Table 1). Mean blood ﬂow rates of
shunts ranged from 93.22 to 164.62 ml/min and
were similar among stent groups.
THROMBOGENICITY ASSESSED BY PLATELET IMMUNO-
FLUORESCENCE. Representative confocal microscopy
images of Xience-EES and comparator biodegrad-
able polymer-coated DES are shown in Figure 2.
Xience-EES demonstrated the least absolute and
percentage of positive ﬂuorescence areas corre-
sponding to aggregated platelets relative to DES
with biodegradable polymer coatings (mean percent
of ﬂuorescence positive area: BioMatrix Flex-BES
27.2%, Synergy-EES 18.0%, Nobori-BES 21.1%,
Orsiro-SES 17.6%, Xience-EES 13.2%) (Table 1). Linear
mixed-effects model procedures demonstrated bio-
logically relevant and statistically signiﬁcant differ-
ences in percent of positive ﬂuorescence areabetween Xience-EES versus BioMatrix Flex-BES
(mean difference: 15.54, 95% conﬁdence interval
[CI]: 11.34 to 19.75, p < 0.001) and Synergy-EES (mean
difference: 8.64, 95% CI: 4.43 to 12.84, p < 0.001)
(Figure 3A). Overall, stent surface area measured by
planimetry was similar between Xience-EES (mean
stent surface area: 6.8 mm2) and BioMatrix Flex-BES
(6.9 mm2, mean difference: 0.068, 95% CI: -0.63 to
0.77 versus Xience-EES, p ¼ 0.99), Synergy-EES (6.3
mm2, mean difference: -0.57, 95% CI: -1.27 to 0.13, p ¼
0.16 versus Xience-EES), and Orsiro-SES (6.6 mm2,
mean difference: -0.20, 95% CI: -0.90 to 0.51, p ¼ 0.93
versus Xience-EES), whereas it was signiﬁcantly
greater for Nobori-BES (8.8 mm2, mean difference:
1.96, 95% CI: 1.26 to 2.65, p < 0.001 versus Xience-
EES) (Tables 1 and 2). When total platelet ﬂuores-
cence area was normalized to stent surface area,
differences remained signiﬁcant among Xience-EES
versus BioMatrix Flex-BES (mean difference: 80.57,
TABLE 1 Quantiﬁed Variables for the Assessment of Platelet Aggregation in Xience-EES and Biodegradable Polymer-Coated DES
in a Swine Shunt Model
BioMatrix Flex-BES Synergy-EES Nobori-BES Orsiro-SES Xience-EES
Absolute ﬂuorescence positive area, mm2 11.73  1.76 8.94  2.00 10.07  2.23 7.89  2.90 7.13  2.92
Percentage of ﬂuorescence positive area, % 27.19  2.90 18.01  4.42 21.07  4.69 17.56  6.71 13.18  6.07
Stent surface area, mm2 6.90  0.35 6.29  0.56 8.80  0.63 6.58  1.17 6.77  0.47
Fluorescent positive area per stent surface area, % 169.48  18.77 144.29  40.71 115.93  30.90 119.87  40.54 105.02  41.63
Number of platelet aggregation clots per stent by CM 7.50  2.74 5.17  4.36 0.50  0.84 2.17  1.47 0.37  0.67
Number of platelet aggregation clots per stent by SEM 3.33  2.25 5.50  3.99 0.17  0.41 2.17  1.60 0.20  0.55
Values are mean  SD.
BES ¼ biolimus-eluting stent(s); CM ¼ confocal microscopy; EES ¼ everolimus-eluting stent(s); SEM ¼ scanning electron microscopy; SES ¼ sirolimus-eluting stent(s);
Xience-EES ¼ Xience Xpedition everolimus-eluting stent.
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125395% CI: 47.51 to 113.64, p < 0.001) and Synergy-EES
(mean difference: 63.16, 95% CI: 30.09 to 96.22, p <
0.001), whereas Nobori-BES and Orsiro-SES were
similar to Xience-EES (Table 2).
The number of platelet aggregate clots >0.1 mm2 as
assessed by confocal microscopy was also least for
Xience-EES (Table 1), where signiﬁcant differencesFIGURE 3 Comparisons of Acute Thrombogenicity and Inﬂammatory
Biodegradable Polymer-Coated DES in a Swine Shunt Model
Linear mixed models showing comparisons of percentage of ﬂuorescent
number of cell nuclei on stent surface as assessed by confocal microsco
biodegradable polymer-coated DES. A mean difference >0 denotes grea
compared with Xience-EES, whereas for mean ratio, a value >1 denotes
DES versus Xience-EES. CI ¼ conﬁdence interval; DES ¼ drug-eluting stwere consistently observed compared with BioMatrix
Flex-BES (mean difference: 7.26, 95% CI: 5.10 to 9.41,
p < 0.001) and Synergy-EES (mean difference: 4.94,
95% CI: 2.79 to 7.10, p < 0.001) (Table 2).
SCANNING ELECTRON MICROSCOPIC ASSESSMENT
OF THROMBOGENICITY. The number of plateletCell Attachment on the Stent Surface Between Xience-EES Versus
positive area (percentage of area occupied by thrombus) (A) and
py (40,6-diamindino-2-phenylindole) (B) between Xience-EES versus
ter levels of the parameter in biodegradable polymer-coated DES as
greater levels of the parameter in biodegradable polymer-coated
ent(s).
TABLE 2 Effect Estimates on the Basis of Nested Linear Mixed Models for Xience-EES
Versus Biodegradable Polymer-Coated DES in a Swine Acute Shunt Model
Mean Difference (95% CI) p Value
Absolute ﬂuorescence positive area, mm2
Xience-EES vs. BioMatrix Flex-BES 15.54 (11.34 to 19.75) <0.001
Xience-EES vs. Synergy-EES 8.64 (4.43 to 12.84) <0.001
Xience-EES vs. Nobori-BES 4.22 (-0.06 to 8.49) 0.055
Xience-EES vs. Orsiro-SES 2.95 (-1.26 to 7.15) 0.286
Stent surface area, mm2
Xience-EES vs. BioMatrix Flex-BES 0.068 (-0.63 to 0.77) 0.99
Xience-EES vs. Synergy-EES -0.57 (-1.27 to 0.13) 0.16
Xience-EES vs. Nobori-BES 1.96 (1.26 to 2.65) <0.001
Xience-EES vs. Orsiro-SES -0.20 (-0.90 to 0.51) 0.93
Fluorescent positive area per stent surface area
Xience-EES vs. BioMatrix Flex-BES 80.57 (47.51 to 113.64) <0.001
Xience-EES vs. Synergy-EES 63.16 (30.09 to 96.22) <0.001
Xience-EES vs. Nobori-BES -13.03 (-46.36 to 20.31) 0.80
Xience-EES vs. Orsiro-SES 9.06 (-24.01 to 42.12) 0.94
Number of platelet aggregation clot per stent by CM
Xience-EES vs. BioMatrix Flex-BES 7.26 (5.10 to 9.41) <0.001
Xience-EES vs. Synergy-EES 4.94 (2.79 to 7.10) <0.001
Xience-EES vs. Nobori-BES 0.26 (-1.90 to 2.41) 0.997
Xience-EES vs. Orsiro-SES 1.79 (-0.36 to 3.94) 0.144
Number of platelet aggregation clot per stent by SEM
Xience-EES vs. BioMatrix Flex-BES 3.23 (1.26 to 5.19) <0.001
Xience-EES vs. Synergy-EES 5.39 (3.42 to 7.36) <0.001
Xience-EES vs. Nobori-BES 0.01 (-1.95 to 1.97) >0.99
Xience-EES vs. Orsiro-SES 1.89 (-0.08 to 3.86) 0.066
A mean difference >0 denotes greater levels of the parameter in biodegradable polymer-coated DES
as compared with Xience-EES.
CI ¼ conﬁdence interval; other abbreviations as in Table 1.
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1254aggregate clots >0.1 mm2 assessed by SEM was also
least for Xience-EES compared with DES with biode-
gradable polymer coatings (Figure 4, Table 1), with
signiﬁcant differences achieved relative to BioMatrix
Flex-BES (mean difference: 3.23, 95% CI: 1.26 to
5.19, p < 0.001) and Synergy-EES (mean difference:
5.39, 95% CI: 3.42 to 7.36, p < 0.001) (Table 2). Platelet
aggregate clots were mostly observed at the point
of the curved strut connectors in BioMatrix Flex-
BES, whereas for the remaining stents they were
typically found at the tip of the crown or near
conjunctive sites involving the crown and the link
(Figures 2 and 4).
INFLAMMATORY CELL ATTACHMENT TO STRUT
SURFACES. Whereas platelet thrombi generally in-
cluded varying numbers of entrapped inﬂammatory
cells, strut surfaces without thrombi also showed
adherent inﬂammatory cells identiﬁed by both
SEM and confocal microscopy using DAPI staining
(Figures 5 and 6). The number of cell nuclei on strut
surfaces was the least for Xience-EES as compared
to biodegradable polymer-coated DES, where asigniﬁcant difference was observed relative to Bio-
Matrix Flex-BES (mean ratio: 4.73, 95% CI: 2.46 to
9.08, p < 0.001), Nobori-BES (mean ratio: 5.97,
95% CI: 3.11 to 11.44, p < 0.001), and Orsiro-SES
(mean ratio: 5.16, 95% CI: 2.69 to 9.91, p < 0.001)
(Figures 3B and 6).DISCUSSION
In the present study, acute thrombogenicity with
respect to platelet aggregation and inﬂammatory cell
adhesion was compared among contemporary dura-
ble (Xience-EES) and biodegradable polymer-coated
stents of variable geometry and different choice of
rapamycin derivatives using an ex vivo arteriovenous
shunt model in swine. With respect to the primary
objective of this study, the most salient ﬁndings
can be denoted as follows. 1) Platelet aggregation
as assessed by speciﬁc platelet markers was signiﬁ-
cantly less in Xience-EES than in BioMatrix Flex-BES
and Synergy-EES, whereas Nobori-BES and Orsiro-
SES showed numerically greater platelet aggregation
than Xience-EES without reaching statistical signiﬁ-
cance. 2) Deposition of acute inﬂammatory cells as
important activators of pro-thrombotic pathways
were also signiﬁcantly less in Xience-EES than in
BioMatrix Flex-BES, Nobori-BES, and Orsiro-SES,
whereas no signiﬁcant difference was observed in
comparison to Synergy-EES. These ﬁndings indicate
that the Xience-EES system design exhibits an
antithrombotic effect relative to biodegradable
polymer-coated DES used in the current study, with
reduced acute platelet aggregation and inﬂammatory
cell deposition.
RELEVANCE OF STENT GEOMETRY, POLYMER COATING,
AND DRUG. The inﬂuence of polymer coating, strut
dimensions, and positioning relative to the vessel
wall was recently noted as a critical factor in an
ex vivo “bench” stent thrombogenicity model (4). In
study by Kolandaivelu et al. (4), polymer-coated
stents were uniformly less thrombogenic as com-
pared to their BMS counterparts. However, that study
exclusively used DES with circumferential durable
polymer coating adopted from ﬁrst- and second-
generation FDA-approved DES, and in this respect
differs substantially from the current investigation
in which both durable and biodegradable polymer
DES, with circumferential or abluminal polymer
coating were assessed. The circumferentially coated
durable ﬂuorinated Xience-EES copolymer (poly
n-butyl methacrylate and vinylidene ﬂuoride and
hexaﬂuoropropylene) exhibited substantially less
platelet aggregation than did most contemporary
FIGURE 4 Representative SEM Images of BioMatrix Flex-BES, Synergy-EES, Nobori-BES, Orsiro-SES, and Xience-EES in a
Swine Shunt Model
Low- (15) and high- (200) power images of scanning electron microscopy showing least platelet aggregation clot formation (red arrows) on
Xience-EES as compared with the other 4 CE-marked biodegradable polymer-coated DES. Abbreviations as in Figures 1 and 2.
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1255biodegradable stent coatings used in the current
study. Furthermore, the current study used an arte-
riovenous porcine shunt model in contrast to the
study by Kolandaivelu et al. (4), which implemented
a modiﬁed Chandler loop system to study acute
thrombogenicity and therefore is less likely to
resemble ﬂow conditions observed in clinical appli-
cations. However, a general statement that all
durable polymers are less thrombogenic than biode-
gradable stent coatings are cannot be derived from
the current study and should not be expected as the
current study also showed substantial differences
among the group of biodegradable stent coatings. To
this extent, BioMatrix Flex-BES and Nobori-BES,
which share similar metal composition, strut thick-
ness, and polymer/drug coating technology, demon-
strated differences in thrombogenicity, indicating
factors other than the above-mentioned ones are
critical to platelet aggregation and acute thrombosis.
One remaining difference between Nobori-BES andBioMatrix Flex-BES pertains to an ultra-thin nonde-
gradable parylene C coating in the former sandwiched
between the stent and the abluminally coated
biodegradable poly-DL lactic acid polymer, which
may have contributed to the different outcomes of
this study (11). The design intent of the parylene C
is to improve coating integrity as in vitro study
with SEM assessment showed poor coating integrity
of BioMatrix Flex-BES (12), which may have also
affected the difference in thrombogenicity between
the 2 stents. The design platform is also substantially
different, whereas the curved strut connector in
BioMatrix Flex-BES to improve ﬂexibility and track-
ability could present a nidus for platelet aggregation
and thrombosis. The impact of differential stent
design on thrombogenicity is likely attributable to the
difference in ﬂow condition and is supported by
previous work in this ﬁeld (4) and the observation of
the current study that greater platelet aggregates
were found within the link connectors of BioMatrix
FIGURE 5 Representative SEM Images of Durable and Biodegradable Polymer-Coated DES Implants From 1 H Ex Vivo Shunts in Swine
Upper pair of rows shows adherent thrombi whereas the lower rows represent inﬂammation (original magniﬁcation: upper and lower rows 600 and 2,000,
respectively).
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1256Flex-BES. It has been shown in the past that strut
thickness exerts an impact on pre-clinical and clin-
ical outcomes of DES (13,14). As both BioMatrix Flex-
BES and Nobori-BES share greater strut thickness
than Xience-EES does, it seems likely that this
highly relevant factor contributed to the overall
study ﬁndings. Nevertheless, increased platelet ag-
gregation in Synergy-EES (74 mm) and Orsiro-SES (60
mm) demonstrated that the advantages such as
reduced strut thickness may be counterbalanced by
other factors involved in acute thrombus formation.
Rapamycin and its derivatives have been shown to
inhibit platelet function via a mammalian target of
rapamycin, or mTOR, inhibition pathway (15,16). A
difference between circumferential polymer-coated
DES, whether of durable or biodegradable poly-
mers, versus abluminal polymer-coated DES is the
active release of drug from the strut sidewall andluminal surfaces contacting the blood. This may
be another factor inﬂuencing the platelet be-
havior with these circumferential versus abluminal
polymer-coated DES.
PATHOLOGIC FINDINGS IN THE SETTING OF ACUTE
STENT THROMBOSIS. ST manifesting within 30 days
remains a clinically relevant issue complicated by
increased mortality and morbidity, despite the
introduction of newer-generation DES (1,2). Under-
lying clinical considerations of early ST include
patient demographics, lesion characteristics, and
procedural factors (17,18), whereas assessment of
acute ST cases at autopsy from patients presenting
with acute coronary syndromes indicate morpho-
logic features such as necrotic core prolapse, medial
tear, and incomplete stent apposition (3) as most
relevant. Whereas a direct association with the main
FIGURE 6 Representative Confocal Images of Durable and Biodegradable Polymer-Coated DES Implants From 1 H Ex Vivo Shunts in Swine
Nuclei stained with 40,6-diamindino-2-phenylindole represent adherent inﬂammatory cells. Abbreviations as in Figures 1 and 2.
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1257ﬁndings of the current study is difﬁcult to establish,
the relevance of suboptimal stent implantation
resulting in deteriorating ﬂow conditions has been
exempliﬁed in our recent autopsy study and
many previous clinical trials (19,20). An additional
important factor contributing to early ST in autopsy
cases of patients presenting with acute coronary
syndromes pertains to the presence of a highly
thrombogenic underlying necrotic core, which, in
the case of sudden exposure to altered arterial
blood ﬂow, ampliﬁes pro-thrombotic pathways irre-
spective of stent design or polymer choice. Therefore,
it is important to understand that experimental
studies such as the current one can only address in-
dividual components contributing to acute ST but
cannot reproduce the complexity of human disease
conditions.
COMPARISON WITH CLINICAL DATA. The low
prevalence of early ST in Xience-EES versus the
ﬁrst-generation DES has recently been reported in
clinical trials (5,6). Data from 13 randomized clinical
trials demonstrated that EES had signiﬁcantly
reduced ST, target lesion revascularization, andmyocardial infarction as compared to other stents
(21). In a network meta-analysis by Palmerini et al.
(5), Xience-EES showed signiﬁcantly lower rates of
deﬁnite ST than did BMS, as well as to ﬁrst- and
other second-generation DES at 1 and 2 years.
Even in the setting of acute ST-segment elevation
myocardial infarction, EES showed reduced rates of
acute and subacute ST compared with those for
the Multi-Link Vision BMS (Medtronic, Minneapolis,
Minnesota). This reinforces the experimental ﬁnd-
ings that, in general, polymeric coatings may pro-
vide a protective barrier against acute thrombus
formation. When directly compared with DES using
biodegradable polymer coating, the COMPARE II
(Comparison of the Everolimus Eluting With the
Biolimus A9 Eluting Stent) and NEXT (Nobori
Biolimus-Eluting Versus Xience/Promus Everolimus-
Eluting Stent Trial) studies reported a substantial
reduction in the risk of ST in Xience-EES as com-
pared to Nobori-BES despite not reaching statistical
signiﬁcance at 1-year follow-up (22,23), which is in
clear agreement with the ﬁndings of the current
study. Considering that durable polymer coatings
have been shown to reduce thrombogenicity as
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1258compared with BMS (4), abluminal polymer coating
(BioMatrix Flex-BES and Synergy-EES) may have
a disadvantage in terms of platelet aggregation
because of exposure of bare-metal on the luminal
surface of the stents.
INFLAMMATION CONTRIBUTING TO ACUTE THROMBUS
FORMATION. Platelet aggregation on the surface of
stent struts is accompanied by recruitment of circu-
lating leukocytes consisting mainly of neutrophils
and monocytes, which can be regarded as an acute
response to vascular injury following stent place-
ment (24,25). Although arterial thrombosis is widely
considered to arise from the exposure of atheroscle-
rotic plaque-derived tissue factor, the role of
leukocyte-born tissue factor in the initiation of this
cascade has recently been demonstrated in an
experimental study on human neutrophils and
monocytes (26). In this study, human leukocytes
were shown to be an important source of tissue
factor, which may predispose atherosclerotic pla-
ques or stented coronary arteries to arterial throm-
bosis in the absence of excessive tissue damage.
Furthermore, it has elegantly been demonstrated
that leukocyte-derived tissue factor can be trans-
ferred to platelets, thereby providing them with a
source to propagate arterial thrombus formation
(27). In addition to the pro-coagulatory pathways
stimulated by release of tissue factor by monocytes,
neutrophils have also been shown to contribute
to arterial thrombosis in a cathepsin-dependent
manner (28). These experimental observations give
rise to the question whether polymeric durable
coatings such as the one used on Xience-EES may
also have important anti-inﬂammatory effects that
amplify the acute protective function against clot
formation.
Previous human autopsy studies have shown that
inﬂammation characterized by macrophage inﬁltra-
tion is associated with increased neointimal thick-
ness (29), whereas the involvement of neutrophils
in the induction of smooth muscle cell prolifera-
tion has also been reported (30). In the current
ex vivo shunt study, numerous inﬂammatory cells
accompanied sites of thrombus formation, and
they were also observed on the surface of stent
struts in the absence of thrombus. Interestingly,
not only abluminal polymer-coated BioMatrix Flex-
BES, Synergy-EES, and Nobori-BES, but also cir-
cumferential polymer-coated Orsiro-SES showed
signiﬁcantly greater inﬂammatory cell attachment
on the stent surface as compared to Xience-EES.
Orsiro-SES has a hybrid coating with passive
PROBIO amorphous silicon carbide (Biotronik) andactive BIOlute high molecular weight poly-L-lactide
acid coating (Biotronik), whereas ﬂuorinated copol-
ymer of Xience-EES consists of poly n-butyl methac-
rylate/vinylidene ﬂuoride and hexaﬂuoropropylene
copolymer. Fluorinated surface coatings for Dacron
grafts have been implied to reduce platelet activa-
tion and thrombogenicity, decrease inﬂammatory
response, and promote faster endothelialization and
healing, which are all desirable characteristics of
stent coatings (31). Our results conﬁrm the known
beneﬁts of ﬂuoropolymer in reducing thrombogenicity
and inﬂammatory cell attachment.
STUDY LIMITATIONS. The results from an ex vivo
shunt model without antiplatelet agents cannot be
directly applied to diseased arteries in living pa-
tients who are generally on dual antiplatelet ther-
apy. Nevertheless, it should be noted that complex
features of diseased arteries in humans generally
do not allow us to directly evaluate an impact of
individual stents on acute thrombogenicity, because
multiple factors can inﬂuence thrombogenicity in
humans, which cannot be fully adjusted. We believe
that the current experiments with similar conditions
across different conduits are appropriate models to
compare acute thrombogenicity in individual stents.
The predisposition toward blood coagulation may
vary between animals, although we have carefully
monitored and evaluated blood coagulation as
well as platelet function during and after the
experiment.CONCLUSIONS
The permanent ﬂuoropolymer-coated Xience-EES
showed signiﬁcantly lower acute thrombogenicity
than did biodegradable polymer-coated BioMatrix
Flex-BES and Synergy-EES, and Xience-EES also
showed less inﬂammatory cell attachment than
did BioMatrix Flex-BES, Nobori-BES, and Orsiro-
SES, in a porcine arteriovenous shunt model.
These ﬁndings highlight the existence of an acute
protective effect of Xience-EES against thrombus
formation.
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PERSPECTIVES
WHAT IS KNOWN? Early stent thrombogenicity is
inﬂuenced by several factors including underlying plaque
morphologies, stent design, choice of polymer coating,
and drugs. Previous experimental studies in modiﬁed
Chandler loops have shown that durable polymer-coated
stents with thin struts exhibit less acute thrombogenicity
with respect to platelet aggregation than do uncoated
stents or stents with thicker struts. It remains unclear
whether relevant differences exist with respect to
acute thrombogenicity, particularly between current
commercial stent designs using permanent polymers
and those using biodegradable polymers.
WHAT IS NEW? We demonstrate that the permanent
ﬂuoropolymer-coated Xience-EES exhibits decreased
acute thrombogenicity relative to contemporary DES
with biodegradable polymer coatings with less platelet
aggregation and inﬂammatory cell attachment in an
ex vivo swine shunt model. Our data support the clinical
ﬁndings of decreased thrombotic events in Xience-EES.
WHAT IS NEXT? Acute thrombogenicity in contem-
porary DES needs to be further evaluated in vivo.
Furthermore, the prevalence of early stent thrombosis
in contemporary DES needs to be investigated in large
randomized clinical trials, especially in patients with
complex coronary artery disease.
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